Sugi Predict

Sugi Predict / Compounds / SCHEMBL3707696

SCHEMBL3707696

SCHEMBL3707696

CC(C)c1c(N)nn2cccnc12

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 4/20 0.49
▸ JAK2 O60674 13/20 0.48
▸ JAK3 P52333 13/20 0.48
▸ SMPD3 Q9NY59 2/20 0.43
▸ FLT3 P36888 1/20 0.39
▸ PIK3CD O00329 2/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ PIK3R2 O00459 1/20 0.36
▸ AXL P30530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14712196 0.81 PIK3CG (0.62) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL12146434 0.81 PIK3CG (0.54) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL21585151 0.80 JAK2 (0.43) PIK3CGJAK2JAK3SMPD3FLT3
SCHEMBL21555747 0.78 HTR6 (0.49) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL25024696 0.77 PIK3CG (0.47) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL15308491 0.77 PIK3CG (0.49) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL5741027 0.76 SMPD3 (0.50) PIK3CGJAK2JAK3SMPD3AXL
SCHEMBL19413040 0.76 JAK2 (0.45) PIK3CGJAK2JAK3SMPD3FLT3
SCHEMBL21555751 0.75 JAK2 (0.41) PIK3CGJAK2JAK3SMPD3
SCHEMBL24880503 0.75 JAK2 (0.41) PIK3CGJAK2JAK3SMPD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773102-B2 Heterocyclic compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2023-10-03 — — US disclosed
US-20230009843-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2023-01-12 — — US disclosed
US-11541059-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2023-01-03 — — US disclosed
US-11091491-B2 Heterocyclic compounds as PI3K-y inhibitors INCYTE CORPORATION (US) 2021-08-17 — — US disclosed
US-10941162-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2021-03-09 — — US disclosed
US-20210000837-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2021-01-07 — — US disclosed
US-20200031837-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2020-01-30 — — US disclosed
US-10472368-B2 Heterocyclic compounds as PI3K-γ inhibitors INCYTE CORPORATION (US) 2019-11-12 — — US disclosed
US-20190330240-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TWELVE THERAPEUTICS, INC. 2019-10-31 — — US disclosed
US-9775844-B2 Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS, INC. (US) 2017-10-03 — — US disclosed
WO-2017161116-A1 ISOTOPOLOGUES OF ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS AND USES THEREOF AS PI3K KINASE INHIBITORS INFINITY PHARMACEUTICALS, INC. (US) 2017-09-21 — — WO disclosed
WO-2017153527-A1 NOVEL INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE GAMMA ASTRAZENECA AB (SE) 2017-09-14 — — WO disclosed
US-20170129899-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS INCYTE CORPORATION 2017-05-11 — — US disclosed
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 — — US disclosed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 — — WO disclosed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122888-A1 Potassium Channel Modulators KCNQ1, KCNQ2, KCNJ2 PIK3CG 859/4885JAK2 1625/4885JAK3 3825/4885
US-11773102-B2 Heterocyclic compounds as PI3K-γ inhibitors PIK3CD, PIK3CG, PIK3R5 PIK3CG 2/4885JAK2 59/4885JAK3 118/4885
US-11091491-B2 Heterocyclic compounds as PI3K-y inhibitors PIK3R5, PIK3CA, PIK3CD PIK3CG 4/4885JAK2 40/4885JAK3 83/4885
US-10472368-B2 Heterocyclic compounds as PI3K-γ inhibitors PIK3CD, PIK3CG, PIK3R5 PIK3CG 2/4885JAK2 59/4885JAK3 118/4885
US-10941162-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB PIK3CG 4/4885JAK2 98/4885JAK3 276/4885
US-11541059-B2 Heterocyclic compounds and uses thereof PIK3CA, PIK3CD, PIK3CB PIK3CG 7/4885JAK2 51/4885JAK3 171/4885
US-20190330240-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB PIK3CG 7/4885JAK2 51/4885JAK3 171/4885
US-20210000837-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB PIK3CG 7/4885JAK2 51/4885JAK3 171/4885
US-20200031837-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD PIK3CG 4/4885JAK2 40/4885JAK3 83/4885
US-20170129899-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD PIK3CG 4/4885JAK2 40/4885JAK3 83/4885
US-20230009843-A1 HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS PIK3R5, PIK3CA, PIK3CD PIK3CG 4/4885JAK2 40/4885JAK3 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.